We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Neurocrine Biosciences has finally launched its once-daily Parkinson’s disease add-on treatment Ongentys (opicapone) in the U.S. following months of delay brought on by the COVID-19 pandemic. Read More
Gilead Sciences has announced that it will spend $21 billion to acquire New Jersey drugmaker Immunomedics as part of its ongoing expansion into immune-oncology treatments. Read More
China’s state-owned pharmaceutical company, Sinopharm, said that it has already vaccinated hundreds of thousands in the country with its COVID-19 vaccine candidates, even though its phase 3 trials have not yet wrapped up. Read More
Regeneron Pharmaceuticals’ investigational COVID-19 antibody cocktail has been added to the UK’s RECOVERY trial aimed at finding effective treatments. Read More
A late-stage trial of Eli Lilly’s rheumatoid arthritis (RA) treatment Olumiant (baricitinib) and Gilead Sciences’ remdesivir found that the combination reduced recovery time in hospitalized COVID-19 patients compared to remdesivir alone. Read More
The UK government has signed a $1.5 billion agreement with Valneva to supply up to 190 million doses of the French company’s COVID-19 vaccine — enough to provide multiple doses to the UK’s population of almost 68 million. Read More
The pharma industry is pledging to take President Trump’s new executive order aimed at lowering drug prices to court even as Trump considers implementing the order ahead of the Nov. 3 presidential election. Read More